Trial Profile

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CPO 301 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Conjupro Biotherapeutics

30 Apr 2025 Results (n=232; as of 26 Dec 2024) presented at the 116th Annual Meeting of the American Association for Cancer Research
16 Jul 2024 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
24 Jul 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com